Ocugen Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Ocugen is gedaald met een gemiddeld jaarlijks percentage van -2%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 36.2%. De inkomsten zijn groeide met een gemiddeld percentage van 40.1% per jaar.
Belangrijke informatie
-2.03%
Groei van de winst
9.05%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.04% |
| Inkomstengroei | 40.10% |
| Rendement op eigen vermogen | -1,234.68% |
| Nettomarge | -1,605.22% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • Jun 05
OCGN: Retinal Gene Therapies Will Gain Momentum With Upcoming 2027 Readouts
Ocugen's analyst price target has edged down by $0.14 to $11.43 as analysts refresh their models around updated expectations for revenue growth, profitability, and long term P/E assumptions following recent gene therapy trial updates and upcoming catalysts across the retinal disease pipeline. Analyst Commentary Recent research updates show a mix of optimism around Ocugen's gene therapy pipeline and some caution on execution risk and timing, which is feeding into the modest reset in the average price target.Narratiefupdate • Apr 26
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.Narratiefupdate • Apr 11
OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.Narratiefupdate • Mar 28
OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.Narratiefupdate • Mar 12
OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.Seeking Alpha • Mar 09
Ocugen: Downgrading After OCU410 Data Release
Summary Ocugen (OCGN) is downgraded from 'Buy' to 'Hold' due to concerns over OCU410's dose response in geographic atrophy. Preliminary phase 2 ArMaDa data showed a 46% reduction in lesion growth, but lacked dose-dependent efficacy and had a small sample size. Key catalysts include final ArMaDa data [March 2026], OCU410ST interim [Q3 2026] and topline [Q2 2027], and OCU400 RP topline [Q1 2027]. Company's cash runway extends to Q4 2026 [potentially Q2 2027 with warrant exercise], but quarterly burn and multiple late-stage trial risks remain. Read the full article on Seeking AlphaNarratiefupdate • Feb 25
OCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.Narratiefupdate • Feb 11
OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.Narratiefupdate • Jan 27
OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.Narratiefupdate • Jan 12
OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.Narratiefupdate • Dec 15
OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.Narratiefupdate • Nov 29
OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.Narratiefupdate • Nov 15
OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.Narratiefupdate • Nov 01
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.Narratiefupdate • Oct 17
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.Narratiefupdate • Oct 03
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
Nieuw narratief • Apr 02
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.Opbrengsten en kosten
Opbrengsten en kosten
Hoe Ocugen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 4 | -72 | 29 | 0 |
| 31 Dec 25 | 4 | -68 | 28 | 0 |
| 30 Sep 25 | 5 | -64 | 28 | 0 |
| 30 Jun 25 | 5 | -57 | 26 | 0 |
| 31 Mar 25 | 5 | -58 | 27 | 0 |
| 31 Dec 24 | 4 | -54 | 27 | 0 |
| 30 Sep 24 | 5 | -51 | 26 | 0 |
| 30 Jun 24 | 7 | -50 | 28 | 0 |
| 31 Mar 24 | 7 | -58 | 30 | 0 |
| 31 Dec 23 | 6 | -63 | 32 | 0 |
| 30 Sep 23 | 7 | -79 | 34 | 0 |
| 30 Jun 23 | 3 | -90 | 34 | 0 |
| 31 Mar 23 | 3 | -86 | 34 | 0 |
| 31 Dec 22 | 2 | -87 | 35 | 0 |
| 30 Sep 22 | 0 | -74 | 36 | 0 |
| 30 Jun 22 | 0 | -63 | 32 | 0 |
| 31 Mar 22 | 0 | -69 | 29 | 0 |
| 31 Dec 21 | 0 | -58 | 23 | 0 |
| 30 Sep 21 | 0 | -48 | 18 | 0 |
| 30 Jun 21 | 0 | -47 | 15 | 0 |
| 31 Mar 21 | 0 | -38 | 10 | 0 |
| 31 Dec 20 | 0 | -34 | 8 | 0 |
| 30 Jun 20 | 0 | -30 | 8 | 1 |
| 31 Mar 20 | 0 | -18 | 7 | -3 |
| 31 Dec 19 | 0 | -20 | 6 | 0 |
| 30 Sep 19 | 0 | -39 | 6 | 9 |
| 30 Jun 19 | 0 | -18 | 6 | 4 |
| 31 Mar 19 | 0 | -19 | 6 | 11 |
| 31 Dec 18 | 0 | -18 | 6 | 10 |
Kwaliteitswinsten: OCGN is momenteel verliesgevend.
Groeiende winstmarge: OCGN is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: OCGN is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 2% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van OCGN over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: OCGN is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 54.5% ).
Rendement op eigen vermogen
Hoge ROE: OCGN heeft een negatief Return on Equity ( -1234.68% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/09 08:39 |
| Aandelenkoers aan het einde van de dag | 2026/06/09 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ocugen, Inc. wordt gevolgd door 8 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |